Switch to:
Also traded in: Argentina, Austria, Brazil, Chile, France, Germany, Mexico, Romania, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.35
MRK's Cash-to-Debt is ranked lower than
77% of the 859 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.03 vs. MRK: 0.35 )
Ranked among companies with meaningful Cash-to-Debt only.
MRK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: 0.69 Max: 1.93
Current: 0.35
0.29
1.93
Equity-to-Asset 0.32
MRK's Equity-to-Asset is ranked lower than
81% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. MRK: 0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
MRK' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.45 Max: 0.53
Current: 0.32
0.32
0.53
Debt-to-Equity 0.94
MRK's Debt-to-Equity is ranked lower than
74% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. MRK: 0.94 )
Ranked among companies with meaningful Debt-to-Equity only.
MRK' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.12  Med: 0.36 Max: 0.94
Current: 0.94
0.12
0.94
Debt-to-EBITDA 1.80
MRK's Debt-to-EBITDA is ranked lower than
55% of the 495 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.92 vs. MRK: 1.80 )
Ranked among companies with meaningful Debt-to-EBITDA only.
MRK' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.87  Med: 1.81 Max: 2.3
Current: 1.8
0.87
2.3
Interest Coverage 11.57
MRK's Interest Coverage is ranked lower than
73% of the 648 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 86.08 vs. MRK: 11.57 )
Ranked among companies with meaningful Interest Coverage only.
MRK' s Interest Coverage Range Over the Past 10 Years
Min: 4.69  Med: 9.63 Max: 13.83
Current: 11.57
4.69
13.83
Piotroski F-Score: 6
Altman Z-Score: 3.94
Beneish M-Score: -2.79
WACC vs ROIC
4.71%
13.34%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 21.12
MRK's Operating Margin % is ranked higher than
72% of the 801 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.97 vs. MRK: 21.12 )
Ranked among companies with meaningful Operating Margin % only.
MRK' s Operating Margin % Range Over the Past 10 Years
Min: 7.3  Med: 17.82 Max: 21.12
Current: 21.12
7.3
21.12
Net Margin % 14.71
MRK's Net Margin % is ranked lower than
58% of the 802 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.32 vs. MRK: 14.71 )
Ranked among companies with meaningful Net Margin % only.
MRK' s Net Margin % Range Over the Past 10 Years
Min: 1.87  Med: 12.15 Max: 47.04
Current: 14.71
1.87
47.04
ROE % 19.48
MRK's ROE % is ranked lower than
56% of the 832 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.94 vs. MRK: 19.48 )
Ranked among companies with meaningful ROE % only.
MRK' s ROE % Range Over the Past 10 Years
Min: 1.52  Med: 10.5 Max: 33.15
Current: 19.48
1.52
33.15
ROA % 7.29
MRK's ROA % is ranked lower than
57% of the 871 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.88 vs. MRK: 7.29 )
Ranked among companies with meaningful ROA % only.
MRK' s ROA % Range Over the Past 10 Years
Min: 0.79  Med: 5.14 Max: 16.2
Current: 7.29
0.79
16.2
ROC (Joel Greenblatt) % 67.98
MRK's ROC (Joel Greenblatt) % is ranked higher than
87% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.23 vs. MRK: 67.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MRK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 10.9  Med: 45.54 Max: 104.88
Current: 67.98
10.9
104.88
3-Year Revenue Growth Rate 4.30
MRK's 3-Year Revenue Growth Rate is ranked lower than
69% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. MRK: 4.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MRK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -24  Med: 8.4 Max: 23.1
Current: 4.3
-24
23.1
3-Year EBITDA Growth Rate 6.00
MRK's 3-Year EBITDA Growth Rate is ranked lower than
86% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. MRK: 6.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MRK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -19.9  Med: 8.8 Max: 43.6
Current: 6
-19.9
43.6
3-Year EPS without NRI Growth Rate 14.10
MRK's 3-Year EPS without NRI Growth Rate is ranked lower than
91% of the 663 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. MRK: 14.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MRK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 7.9 Max: 73.8
Current: 14.1
0
73.8
GuruFocus has detected 4 Warning Signs with Merck & Co Inc MRK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MRK's 30-Y Financials

Financials (Next Earnings Date: 2019-04-30)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2018

MRK Guru Trades in Q1 2018

Steven Cohen 1,740,873 sh (New)
Ken Fisher 7,648,258 sh (+4.08%)
Joel Greenblatt 742,473 sh (+3.65%)
Charles Brandes 1,768,152 sh (+7.69%)
Robert Bruce 359,400 sh (+38.55%)
Richard Pzena 4,524,430 sh (+175.79%)
Murray Stahl 47,659 sh (+0.23%)
John Buckingham 46,083 sh (+4.35%)
Jeremy Grantham 2,774,838 sh (+460.38%)
Paul Tudor Jones 63,992 sh (+259.65%)
Mairs and Power 93,321 sh (+9.29%)
Caxton Associates 22,036 sh (+14.15%)
Pioneer Investments 5,922,828 sh (+14.09%)
Mario Gabelli 107,759 sh (+0.05%)
Ray Dalio 196,010 sh (+27.94%)
Richard Snow 5,327 sh (unchged)
Tom Gayner 5,600 sh (unchged)
David Carlson 275,000 sh (unchged)
Steven Cohen 2,700,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 192,999 sh (unchged)
Smead Value Fund 592,356 sh (unchged)
First Eagle Investment Sold Out
Tom Russo Sold Out
Jim Simons Sold Out
Vanguard Health Care Fund 24,339,344 sh (-10.53%)
T Rowe Price Equity Income Fund 3,690,000 sh (-2.12%)
Dodge & Cox 13,788,353 sh (-0.04%)
Kahn Brothers 904,387 sh (-1.61%)
PRIMECAP Management 3,411,200 sh (-38.81%)
Jeff Auxier 160,031 sh (-0.29%)
Barrow, Hanley, Mewhinney & Strauss 12,777,977 sh (-10.06%)
» More
Q2 2018

MRK Guru Trades in Q2 2018

Tweedy Browne 3,306 sh (New)
John Hussman 35,000 sh (New)
Ken Fisher 7,928,206 sh (+3.66%)
Richard Pzena 4,904,336 sh (+8.40%)
Jeremy Grantham 3,933,476 sh (+41.76%)
Pioneer Investments 6,653,066 sh (+12.33%)
Eaton Vance Worldwide Health Sciences Fund 658,673 sh (+241.28%)
Richard Snow 5,327 sh (unchged)
Robert Bruce 359,400 sh (unchged)
PRIMECAP Management 3,411,200 sh (unchged)
David Carlson 275,000 sh (unchged)
Louis Moore Bacon 50,000 sh (unchged)
Tom Gayner Sold Out
Paul Tudor Jones Sold Out
Caxton Associates Sold Out
Vanguard Health Care Fund 23,026,644 sh (-5.39%)
T Rowe Price Equity Income Fund 3,650,000 sh (-1.08%)
Dodge & Cox 3,305,109 sh (-76.03%)
Joel Greenblatt 390,114 sh (-47.46%)
Charles Brandes 1,738,819 sh (-1.66%)
Kahn Brothers 897,077 sh (-0.81%)
Murray Stahl 47,331 sh (-0.69%)
John Buckingham 45,685 sh (-0.86%)
Steven Cohen 1,121,700 sh (-35.57%)
Mairs and Power 90,969 sh (-2.52%)
Barrow, Hanley, Mewhinney & Strauss 6,452,964 sh (-49.50%)
Mario Gabelli 103,250 sh (-4.18%)
Ray Dalio 189,089 sh (-3.53%)
Jeff Auxier 153,531 sh (-4.06%)
Smead Value Fund 588,547 sh (-0.64%)
» More
Q3 2018

MRK Guru Trades in Q3 2018

Daniel Loeb 4,500,000 sh (New)
Ken Fisher 8,046,143 sh (+1.49%)
Eaton Vance Worldwide Health Sciences Fund 699,267 sh (+6.16%)
Mario Gabelli 107,250 sh (+3.87%)
Jeremy Grantham 3,972,987 sh (+1.00%)
Pioneer Investments 7,623,431 sh (+14.59%)
John Buckingham 46,945 sh (+2.76%)
David Carlson 275,000 sh (unchged)
Robert Bruce 359,400 sh (unchged)
PRIMECAP Management 3,411,200 sh (unchged)
Tweedy Browne 3,306 sh (unchged)
Murray Stahl 47,331 sh (unchged)
John Hussman Sold Out
Steven Cohen Sold Out
T Rowe Price Equity Income Fund 3,580,000 sh (-1.92%)
Kahn Brothers 886,740 sh (-1.15%)
Vanguard Health Care Fund 22,302,444 sh (-3.15%)
Charles Brandes 1,705,255 sh (-1.93%)
Richard Pzena 4,817,760 sh (-1.77%)
Barrow, Hanley, Mewhinney & Strauss 5,667,956 sh (-12.17%)
Richard Snow 5,320 sh (-0.13%)
Ray Dalio 111,299 sh (-41.14%)
Mairs and Power 89,233 sh (-1.91%)
Joel Greenblatt 358,630 sh (-8.07%)
Jeff Auxier 153,131 sh (-0.26%)
Dodge & Cox 992,263 sh (-69.98%)
Smead Value Fund 575,343 sh (-2.24%)
» More
Q4 2018

MRK Guru Trades in Q4 2018

Spiros Segalas 3,906,019 sh (New)
Tom Russo 2,786 sh (New)
Ken Fisher 8,426,316 sh (+4.72%)
Eaton Vance Worldwide Health Sciences Fund 765,329 sh (+9.45%)
David Carlson 310,000 sh (+12.73%)
Pioneer Investments 9,188,647 sh (+20.53%)
Joel Greenblatt 450,491 sh (+25.61%)
Tweedy Browne 3,306 sh (unchged)
PRIMECAP Management 3,411,200 sh (unchged)
Richard Snow 5,320 sh (unchged)
Robert Bruce 359,400 sh (unchged)
Ray Dalio Sold Out
T Rowe Price Equity Income Fund 3,275,000 sh (-8.52%)
Kahn Brothers 878,762 sh (-0.90%)
Vanguard Health Care Fund 19,164,599 sh (-14.07%)
Mario Gabelli 106,291 sh (-0.89%)
Smead Value Fund 560,356 sh (-2.60%)
Richard Pzena 3,680,967 sh (-23.60%)
Daniel Loeb 2,775,000 sh (-38.33%)
Charles Brandes 1,450,831 sh (-14.92%)
Jeremy Grantham 3,549,542 sh (-10.66%)
Jeff Auxier 132,056 sh (-13.76%)
Mairs and Power 88,148 sh (-1.22%)
Murray Stahl 46,660 sh (-1.42%)
Dodge & Cox 830,025 sh (-16.35%)
Barrow, Hanley, Mewhinney & Strauss 3,219,042 sh (-43.21%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:MRK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:ABBV, XSWX:NOVN, XSWX:ROG, XTER:BAYN, LSE:GSK, NYSE:PFE, XPAR:SAN, NYSE:LLY, LSE:AZN, NYSE:BMY, TSE:4503, TSE:4519, TSE:4578, TSE:4568, HKSE:01093, TSE:4151, TSE:4528, SHSE:600436, SHSE:600867, SZSE:002422 » details
Traded in other countries:MRK.Argentina, MRK.Austria, MRCK34.Brazil, MRK.Chile, MRK.France, 6MK.Germany, MRK.Mexico, MRK.Romania, MRK.Switzerland, 0QAH.UK,
Headquarter Location:USA
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiovascular disease, asthma, cancer, and infections. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. From a geographical perspective, close to half of the company's sales are generated in the United States.

Guru Investment Theses on Merck & Co Inc

Jeff Auxier Comments on Merck & Co. - Feb 12, 2019

Merck & Co. (NYSE:MRK)



Merck is known for its signature drug, Keytruda, an immunotherapy drug currently registered to treat seven different types of cancer that brings in nearly $2 billion quarterly. Despite having a blockbuster drug that is still on the upswing, Merck has continued to strengthen their pipeline and invest in new drugs such as Gardasil, an HPV vaccine that is already bringing in over $1 billion per quarter, and Bridion, the first selective relaxant binding agent on the market.

From Jeff Auxier (Trades, Portfolio)'s fourth-quarter 2018 market commentary.

Check out Jeff Auxier latest stock trades

Jeff Auxier Comments on Merck and Co. - Aug 08, 2018

Merck and Co., Inc (NYSE:MRK)



Merck beat estimates in the second quarter of 2018 with $10.5 billion in revenues and EPS of $1.06. They were buoyed in the quarter by their signature cancer drug KEYTRUDA which allows the body’s immune system to destroy cancerous cells by blocking a protective enzyme in cancer cells. Sales grew 89% in the quarter to $1.667 billion and are expected to continue to grow to upwards of $13 billion annually by 2026. Recently KEYTRUDA was approved in China and the EU for metastatic melanoma.

From Jeff Auxier (Trades, Portfolio)'s second quarter 2018 shareholder letter.

Check out Jeff Auxier latest stock trades

Jeff Auxier Comments on Merck & Co. - Feb 06, 2018

Merck & Co. (NYSE:MRK) had a challenging quarter as total sales declined 2% due to a temporary production shutdown from a cyber-attack. Merck’s Pharmaceutical segment–making up 89% of sales–fell 3% as they lost market exclusivity for two of their top cholesterol treatments and are facing increasing pricing pressure on their top-selling drug. On a positive note, the outlook for cancer-fighting immunotherapy Keytruda is very encouraging.



From Jeff Auxier (Trades, Portfolio)'s fourth quarter 2018 shareholder letter.

Check out Jeff Auxier latest stock trades

Top Ranked Articles about Merck & Co Inc

Biogen, BioMarin, Lilly and Bristol-Myers Could Be in Crosshairs of Acquirers Merck and Pfizer may be considering mega deals to help offset government price pressures
Merck (MRK) shares have been on a roll the past year, up nearly 50% to more than $80 in the past year. Yet, despite outstanding fourth quarter and full-year results, the more than $43 billion pharma giant may be on the lookout for acquisitions to help spur growth. Read more...
Jeff Auxier Comments on Merck & Co. Guru stock highlight
Merck & Co. (NYSE:MRK)
Read more...
New Research: Key Drivers of Growth for Merck & Co., ON Semiconductor, General Mills, Prudential Financial, Nanometrics, and Echo Global Logistics — Factors of Influence, Major Initiatives and Sustained Production
Wall Street Green on Positive Jobs Report Merck posts stronger-than-expected earnings
U.S. stocks were in positive territory on Friday, driven by a strong report on the U.S. labor market. The economy gained 304,000 new jobs in January,  which was more than expected. However, the unemployment rate rose to 4.0% from 3.9% in December. The Dow Jones Industrial Average advanced 0.49% to 25,124, the S&P 500 index gained 0.19% to 2,709 and the Nasdaq Composite Index rose 0.01% to 7,282. Read more...
Merck Publishes Corporate Responsibility Report
The FDA Approves Merck's Anti-HIV-1 Drugs Merck's products represent a treatment option for chronically infected adult patients in the US
The health care company Merck & Co. Inc. (NYSE:MRK) informed the market Thursday that it has received approval from the Food and Drug Administration for its drugs Delstrigo and Pifeltro for the treatment of U.S. adult patients who are chronically infected with type one of the human immunodeficiency virus (HIV-1). Read more...
Healthy Interactions and Merck Announce Launch of Digital Health Platform Designed to Enhance Patient Engagement in Diabetes Management
Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Jeff Auxier Comments on Merck and Co. Guru stock highlight
Merck and Co., Inc (NYSE:MRK)
Read more...

Ratios

vs
industry
vs
history
PE Ratio 35.74
MRK's PE Ratio is ranked lower than
94% of the 557 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.77 vs. MRK: 35.74 )
Ranked among companies with meaningful PE Ratio only.
MRK' s PE Ratio Range Over the Past 10 Years
Min: 6.33  Med: 30.53 Max: 138.33
Current: 35.74
6.33
138.33
Forward PE Ratio 17.45
MRK's Forward PE Ratio is ranked higher than
73% of the 111 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.60 vs. MRK: 17.45 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 35.74
MRK's PE Ratio without NRI is ranked lower than
94% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.20 vs. MRK: 35.74 )
Ranked among companies with meaningful PE Ratio without NRI only.
MRK' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.33  Med: 30.53 Max: 138.33
Current: 35.74
6.33
138.33
Price-to-Owner-Earnings 31.13
MRK's Price-to-Owner-Earnings is ranked lower than
99.99% of the 324 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 31.95 vs. MRK: 31.13 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MRK' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 6.35  Med: 16.62 Max: 99.18
Current: 31.13
6.35
99.18
PB Ratio 8.08
MRK's PB Ratio is ranked lower than
77% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.64 vs. MRK: 8.08 )
Ranked among companies with meaningful PB Ratio only.
MRK' s PB Ratio Range Over the Past 10 Years
Min: 1.72  Med: 3.26 Max: 8.09
Current: 8.08
1.72
8.09
PS Ratio 5.24
MRK's PS Ratio is ranked lower than
61% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. MRK: 5.24 )
Ranked among companies with meaningful PS Ratio only.
MRK' s PS Ratio Range Over the Past 10 Years
Min: 2.01  Med: 3.38 Max: 5.25
Current: 5.24
2.01
5.25
Price-to-Free-Cash-Flow 26.68
MRK's Price-to-Free-Cash-Flow is ranked lower than
56% of the 298 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.84 vs. MRK: 26.68 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MRK' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.88  Med: 16.87 Max: 88.07
Current: 26.68
7.88
88.07
Price-to-Operating-Cash-Flow 20.30
MRK's Price-to-Operating-Cash-Flow is ranked lower than
56% of the 392 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.00 vs. MRK: 20.30 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MRK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.68  Med: 14.52 Max: 35.61
Current: 20.3
6.68
35.61
EV-to-EBIT 24.31
MRK's EV-to-EBIT is ranked lower than
76% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.85 vs. MRK: 24.31 )
Ranked among companies with meaningful EV-to-EBIT only.
MRK' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.2  Med: 21.8 Max: 52.5
Current: 24.31
5.2
52.5
EV-to-EBITDA 16.49
MRK's EV-to-EBITDA is ranked lower than
57% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.24 vs. MRK: 16.49 )
Ranked among companies with meaningful EV-to-EBITDA only.
MRK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.4  Med: 10.3 Max: 22.6
Current: 16.49
4.4
22.6
EV-to-Revenue 5.44
MRK's EV-to-Revenue is ranked lower than
62% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.24 vs. MRK: 5.44 )
Ranked among companies with meaningful EV-to-Revenue only.
MRK' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.9  Med: 3.8 Max: 5.5
Current: 5.44
1.9
5.5
Shiller PE Ratio 35.07
MRK's Shiller PE Ratio is ranked higher than
57% of the 252 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.75 vs. MRK: 35.07 )
Ranked among companies with meaningful Shiller PE Ratio only.
MRK' s Shiller PE Ratio Range Over the Past 10 Years
Min: 8.3  Med: 20.23 Max: 35.1
Current: 35.07
8.3
35.1
Current Ratio 1.17
MRK's Current Ratio is ranked lower than
75% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. MRK: 1.17 )
Ranked among companies with meaningful Current Ratio only.
MRK' s Current Ratio Range Over the Past 10 Years
Min: 0.97  Med: 1.43 Max: 2.04
Current: 1.17
0.97
2.04
Quick Ratio 0.92
MRK's Quick Ratio is ranked lower than
72% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.87 vs. MRK: 0.92 )
Ranked among companies with meaningful Quick Ratio only.
MRK' s Quick Ratio Range Over the Past 10 Years
Min: 0.69  Med: 1.13 Max: 1.66
Current: 0.92
0.69
1.66
Days Inventory 143.27
MRK's Days Inventory is ranked lower than
62% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 119.80 vs. MRK: 143.27 )
Ranked among companies with meaningful Days Inventory only.
MRK' s Days Inventory Range Over the Past 10 Years
Min: 125.52  Med: 137.75 Max: 209.2
Current: 143.27
125.52
209.2
Days Sales Outstanding 61.02
MRK's Days Sales Outstanding is ranked higher than
65% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 81.76 vs. MRK: 61.02 )
Ranked among companies with meaningful Days Sales Outstanding only.
MRK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 57.26  Med: 60.47 Max: 87.87
Current: 61.02
57.26
87.87
Days Payable 89.65
MRK's Days Payable is ranked higher than
53% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 76.32 vs. MRK: 89.65 )
Ranked among companies with meaningful Days Payable only.
MRK' s Days Payable Range Over the Past 10 Years
Min: 38.91  Med: 59.53 Max: 90.53
Current: 89.65
38.91
90.53

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.47
MRK's Dividend Yield % is ranked higher than
76% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. MRK: 2.47 )
Ranked among companies with meaningful Dividend Yield % only.
MRK' s Dividend Yield % Range Over the Past 10 Years
Min: 2.42  Med: 3.58 Max: 6.68
Current: 2.47
2.42
6.68
Dividend Payout Ratio 0.86
MRK's Dividend Payout Ratio is ranked lower than
98% of the 477 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. MRK: 0.86 )
Ranked among companies with meaningful Dividend Payout Ratio only.
MRK' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.27  Med: 1.01 Max: 5.43
Current: 0.86
0.27
5.43
3-Year Dividend Growth Rate 3.20
MRK's 3-Year Dividend Growth Rate is ranked lower than
66% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. MRK: 3.20 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
MRK' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 4.3 Max: 18.7
Current: 3.2
0
18.7
Forward Dividend Yield % 2.68
MRK's Forward Dividend Yield % is ranked higher than
75% of the 719 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.66 vs. MRK: 2.68 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.82
MRK's 5-Year Yield-on-Cost % is ranked higher than
67% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.12 vs. MRK: 2.82 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
MRK' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.76  Med: 4.09 Max: 7.63
Current: 2.82
2.76
7.63
3-Year Average Share Buyback Ratio 2.20
MRK's 3-Year Average Share Buyback Ratio is ranked higher than
96% of the 571 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -5.30 vs. MRK: 2.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MRK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13  Med: 1.2 Max: 2.8
Current: 2.2
-13
2.8

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.23
MRK's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
58% of the 374 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. MRK: 2.23 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MRK' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.85  Med: 1.47 Max: 3.48
Current: 2.23
0.85
3.48
Price-to-Median-PS-Value 1.56
MRK's Price-to-Median-PS-Value is ranked lower than
72% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.94 vs. MRK: 1.56 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MRK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.7  Med: 1.16 Max: 2.11
Current: 1.56
0.7
2.11
Earnings Yield (Greenblatt) % 4.12
MRK's Earnings Yield (Greenblatt) % is ranked higher than
50% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.31 vs. MRK: 4.12 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MRK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.9  Med: 4.6 Max: 19.3
Current: 4.12
1.9
19.3
Forward Rate of Return (Yacktman) % -3.99
MRK's Forward Rate of Return (Yacktman) % is ranked lower than
76% of the 421 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.96 vs. MRK: -3.99 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MRK' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -4  Med: 8.6 Max: 25.1
Current: -3.99
-4
25.1

More Statistics

Revenue (TTM) (Mil) $42,294.00
EPS (TTM) $ 2.32
Beta0.41
Volatility14.29%
52-Week Range $52.83 - 82.72
Shares Outstanding (Mil)2,581.22

Analyst Estimate

Dec19 Dec20 Dec21
Revenue (Mil $) 45,408 48,240 49,422
EBIT (Mil $) 14,590 16,977 18,781
EBITDA (Mil $) 18,271 20,780 21,340
EPS ($) 3.93 4.68 5.52
EPS without NRI ($) 3.93 4.68 5.52
EPS Growth Rate
(Future 3Y To 5Y Estimate)
8.53%
Dividends per Share ($) 2.25 2.27 2.30

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}